Clinica Imbanaco S.A.S

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• High blood pressure4 trials
• Pulmonary arterial hypertension4 trials
• Stroke2 trials
• Acute lymphoblastic leukaemia1 trial
• Childhood cancers1 trial
• Heart failure1 trial
• Macular degeneration1 trial

Phase

• Phase 37 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Active, not recruiting3 trials
• Completed3 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Actelion3 trials
• Bayer3 trials
• Amgen1 trial
• EyeBiotech Ltd.1 trial
• X4 Pharmaceuticals1 trial

Running trials

• Recruiting

  A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

  NCT07496567· Phase 2/3· EyeBiotech Ltd.· Source

  Contact: Study Coordinator

• Recruiting

  A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

  NCT06056297· Phase 3· X4 Pharmaceuticals· Source

  Contact: Patient Affairs and Advocacy

• Active, not recruiting

  Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Phase 3· Actelion· Source

• Active, not recruiting

  A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

  NCT04175600· Phase 3· Actelion· Source

• Active, not recruiting

  Riociguat in Children With Pulmonary Arterial Hypertension (PAH)

  NCT02562235· Phase 3· Bayer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration1 recruiting

Closed trials

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Actelion· Source

• Completed

  Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

  NCT02303821· Phase 1· Amgen· Source